Business description: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows:

- discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;

- development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ;

- development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies.

Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%).

Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).

Number of employees: 19,000

Sales by Activity: Charles River Laboratories International, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Discovery and Safety Assessment (DSA)

2.11B 2.45B 2.62B 2.45B 2.4B

Research Models and Services (RMS)

690M 739M 792M 829M 846M

Manufacturing Solutions (Manufacturing)

742M 790M 721M 769M 766M

Geographical breakdown of sales: Charles River Laboratories International, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States (U.S)

1.93B 2.34B 2.35B 2.24B 2.14B

Europe

1.04B 1.03B 1.08B 1.08B 1.1B

Canada

339M 399M 487M 482M 501M

Asia Pacific

223M 193M 201M 197M 205M

Other

7.29M 9.96M 16.85M 52.82M 64.86M

Executive Committee: Charles River Laboratories International, Inc.

Manager TitleAgeSince
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Chief Tech/Sci/R&D Officer - 31/12/2013
Chief Tech/Sci/R&D Officer - 31/01/2021
Chief Operating Officer 56 10/11/2021

Composition of the Board of Directors: Charles River Laboratories International, Inc.

Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 -
Director/Board Member 69 04/07/2017
Director/Board Member 70 30/09/2019
Director/Board Member 68 27/02/2020
Director/Board Member 60 15/10/2020
Director/Board Member 73 02/12/2013
Director/Board Member 53 21/01/2024
Director/Board Member 64 19/05/2025
Director/Board Member 62 19/05/2025

Shareholders: Charles River Laboratories International, Inc.

NameEquities%Valuation
Vanguard Capital Management LLC
7.366 %
3,634,376 7.366 % 607 M $
BlackRock Advisors LLC
6.586 %
3,249,416 6.586 % 543 M $
Vanguard Capital Management LLC
6.49 %
3,202,204 6.49 % 535 M $
Invesco Advisers, Inc.
5.464 %
2,696,150 5.464 % 450 M $
Invesco Capital Management LLC
4.858 %
2,397,252 4.858 % 400 M $

Company details: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

251 Ballardvale Street

01887, Wilmington

+781 222 6000

http://www.criver.com
address Charles River Laboratories International, Inc.(CRL)

Group companies: Charles River Laboratories International, Inc.

NameCategory and Sector
Pharmaceuticals: Major
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services

Other Biotechnology & Medical Research

Change 5d. change 1-year change 3-years change Capi.($)
+0.14%-2.11%+21.54%-13.82% 8.11B
+0.27%-0.23%-18.25%-17.11% 43.3B
+1.39%+6.03%+35.81%+28.81% 34.55B
+1.09%-1.47%+260.51%+468.77% 30.65B
+0.87%+8.77%+17.50%-7.80% 28.97B
+1.05%-2.28%+27.24%+25.20% 27.29B
-0.43%+3.91% - - 14.82B
-3.59%-3.69%+173.57%+4,035.93% 13.51B
+0.60%+0.50%+135.06%+113.07% 12.46B
+1.16%+2.32%+5.08%-2.31% 12.13B
Average +0.14%+2.21%+73.12%+514.53% 22.58B
Weighted average by Cap. +0.38%+1.97%+66.10%+336.04%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
168.46USD
Average target price
209.00USD
Spread / Average Target
+24.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Company Charles River Laboratories International, Inc.